You are here

  • Home
  • Archive
  • Volume 72, Issue Suppl 3
  • AB0176 Mmp-3 as a predictor that identifies a subgroup with potential radiographic progression requiring additional biologics to halt future progression among the rheumatoid arthritis patients succeedingly treated with methotrexate (mtx) alone.

Article info

Article menu
Download PDFPDF
Abstracts accepted for publication
Rheumatoid arthritis - prognosis, predictors and outcome
AB0176 Mmp-3 as a predictor that identifies a subgroup with potential radiographic progression requiring additional biologics to halt future progression among the rheumatoid arthritis patients succeedingly treated with methotrexate (mtx) alone.

Authors

Citation

Shiozawa K, Tanaka Y, Yoshihara R, et al
AB0176 Mmp-3 as a predictor that identifies a subgroup with potential radiographic progression requiring additional biologics to halt future progression among the rheumatoid arthritis patients succeedingly treated with methotrexate (mtx) alone.
Annals of the Rheumatic Diseases 2013;72:A839.

Publication history

  • First published January 23, 2014.
Online issue publication 
April 13, 2016

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© 2013, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions